Skip to main content
Top
Published in: Trials 1/2022

Open Access 01-12-2022 | Heart Surgery | Study protocol

The effect of continuing versus withholding angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers on mortality and major adverse cardiovascular events in hypertensive patients undergoing elective non-cardiac surgery: study protocol for a multi-centric open-label randomised controlled trial

Authors: Satyajeet Misra, Satyen Parida, Raj Sahajanandan, Bikram Kishore Behera, Muthapillai Senthilnathan, Ramamani Mariappan, Tony Thomson Chandy, For the ACE investigators

Published in: Trials | Issue 1/2022

Login to get access

Abstract

Background

Angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) are commonly prescribed to patients with hypertension. These drugs are cardioprotective in addition to their blood pressure-lowering effects. However, it is debatable whether hypertensive patients who present for non-cardiac surgery should continue or discontinue these drugs preoperatively. Continuing the drugs entails the risk of perioperative refractory hypotension and/or angioneurotic oedema, while discontinuing the drugs entails the risk of rebound hypertension and myocardial ischaemia. The aim of this study is to evaluate the effect of continuation vs withholding of ACEIs/ARBs on mortality and other major outcomes in hypertensive patients undergoing elective non-cardiac surgery.

Methods

The continuing vs withholding of ACEIs/ARBs in patients undergoing non-cardiac surgery is a prospective, multi-centric, open-label randomised controlled trial. Two thousand one hundred hypertensive patients receiving ACEIs/ARBs and planned for elective non-cardiac surgery will be enrolled. They will be randomised to either continue the ACEIs/ARBs including on the day of surgery (group A) or to withhold it 24–36 h before surgery (group B). The primary endpoint will be the difference in the composite outcome of all-cause in-hospital/30-day mortality and major adverse cardiovascular and non-cardiovascular events. Secondary endpoints will be to evaluate the differences in perioperative hypotension, angioneurotic oedema, myocardial injury, ICU and hospital stay. The impact of the continuation vs withholding of the ACEIs/ARBs on the incidence of case cancellation will also be studied.

Discussion

The results of this trial should provide sufficient evidence on whether to continue or withhold ACEIs/ARBs before major non-cardiac surgery.

Trial registration

Clinical Trials Registry of India CTRI/2021/01/030199. Registered on 4 January 2021
Appendix
Available only for authorised users
Literature
1.
go back to reference Weiser TG, Regenbogen SE, Thompson KD, et al. An estimation of the global volume of surgery: a modelling strategy based on available data. Lancet. 2008;372:139–44.CrossRef Weiser TG, Regenbogen SE, Thompson KD, et al. An estimation of the global volume of surgery: a modelling strategy based on available data. Lancet. 2008;372:139–44.CrossRef
2.
go back to reference Chopra HK, Sambi RS, Krishna CK, et al. Perioperative cardiac assessment and rationale for use of beta-blockers. Ind Heart J. 2010;62:158–67. Chopra HK, Sambi RS, Krishna CK, et al. Perioperative cardiac assessment and rationale for use of beta-blockers. Ind Heart J. 2010;62:158–67.
3.
go back to reference Roshanov PS, Rochwerg B, Patel A, et al. Withholding versus continuing angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers before noncardiac surgery: an analysis of the vascular events in noncardiac surgery patients cohort evaluation prospective cohort. Anesthesiology. 2017;126:16–27.CrossRef Roshanov PS, Rochwerg B, Patel A, et al. Withholding versus continuing angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers before noncardiac surgery: an analysis of the vascular events in noncardiac surgery patients cohort evaluation prospective cohort. Anesthesiology. 2017;126:16–27.CrossRef
5.
go back to reference Foucrier A, Rodseth R, Aissaoui M, et al. The long-term impact of early cardiovascular therapy intensification for postoperative troponin elevation after major vascular surgery. Anesth Analg. 2014;119:1053–63.CrossRef Foucrier A, Rodseth R, Aissaoui M, et al. The long-term impact of early cardiovascular therapy intensification for postoperative troponin elevation after major vascular surgery. Anesth Analg. 2014;119:1053–63.CrossRef
6.
go back to reference Vassallo MC, Tartamella F, Testa F. To stop or not? Withholding anti-hypertensive therapy before surgery is not safe. J Cardiothorac Vasc Anesth. 2017;31:e79–99.CrossRef Vassallo MC, Tartamella F, Testa F. To stop or not? Withholding anti-hypertensive therapy before surgery is not safe. J Cardiothorac Vasc Anesth. 2017;31:e79–99.CrossRef
7.
go back to reference Balzer F, Aronson S, Campagna JA, et al. High postoperative blood pressure after cardiac surgery is associated with acute kidney injury and death. J Cardiothorac Vasc Anesth. 2016;30:1562–70.CrossRef Balzer F, Aronson S, Campagna JA, et al. High postoperative blood pressure after cardiac surgery is associated with acute kidney injury and death. J Cardiothorac Vasc Anesth. 2016;30:1562–70.CrossRef
8.
go back to reference Myles PS, Bellomo R, Corcoran T, Forbes A, Peyton P, Story D, et al. Restrictive versus liberal fluid therapy for major abdominal surgery. N Engl J Med. 2018;378:2263–74.CrossRef Myles PS, Bellomo R, Corcoran T, Forbes A, Peyton P, Story D, et al. Restrictive versus liberal fluid therapy for major abdominal surgery. N Engl J Med. 2018;378:2263–74.CrossRef
9.
go back to reference Kidney Disease: Improving Global Outcome (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–138.CrossRef Kidney Disease: Improving Global Outcome (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–138.CrossRef
10.
go back to reference O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549–56.CrossRef O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549–56.CrossRef
12.
go back to reference Hollmann C, Fernandes NL, Biccard BM. A systematic review of outcomes associated with withholding or continuing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers before noncardiac surgery. Anesth Analg. 2018;127:678–87.CrossRef Hollmann C, Fernandes NL, Biccard BM. A systematic review of outcomes associated with withholding or continuing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers before noncardiac surgery. Anesth Analg. 2018;127:678–87.CrossRef
13.
go back to reference Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2014;64:e77–e137.CrossRef Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2014;64:e77–e137.CrossRef
14.
go back to reference Duceppe E, Parlow J, MacDonald P, et al. Canadian Cardiovascular Society guidelines on perioperative cardiac risk assessment and management for patients who undergo noncardiac surgery. Can J Cardiol. 2017;33:17–32.CrossRef Duceppe E, Parlow J, MacDonald P, et al. Canadian Cardiovascular Society guidelines on perioperative cardiac risk assessment and management for patients who undergo noncardiac surgery. Can J Cardiol. 2017;33:17–32.CrossRef
15.
go back to reference Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA guidelines on non-cardiac surgery: cardiovascular assessment and management: the joint task force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J. 2014;35:2383–431.CrossRef Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA guidelines on non-cardiac surgery: cardiovascular assessment and management: the joint task force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J. 2014;35:2383–431.CrossRef
16.
go back to reference Yang YF, Zhu YJ, Long YQ, et al. Withholding vs. continuing angiotensin-converting enzyme inhibitors or angiotensin receptor blockers before non-cardiac surgery in older patients: study protocol for a multicenter randomized controlled trial. Front Med (Lausanne). 2021;8:654700. https://doi.org/10.3389/fmed.2021.654700.CrossRef Yang YF, Zhu YJ, Long YQ, et al. Withholding vs. continuing angiotensin-converting enzyme inhibitors or angiotensin receptor blockers before non-cardiac surgery in older patients: study protocol for a multicenter randomized controlled trial. Front Med (Lausanne). 2021;8:654700. https://​doi.​org/​10.​3389/​fmed.​2021.​654700.CrossRef
Metadata
Title
The effect of continuing versus withholding angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers on mortality and major adverse cardiovascular events in hypertensive patients undergoing elective non-cardiac surgery: study protocol for a multi-centric open-label randomised controlled trial
Authors
Satyajeet Misra
Satyen Parida
Raj Sahajanandan
Bikram Kishore Behera
Muthapillai Senthilnathan
Ramamani Mariappan
Tony Thomson Chandy
For the ACE investigators
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Trials / Issue 1/2022
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-022-06616-y

Other articles of this Issue 1/2022

Trials 1/2022 Go to the issue